Page 16 - நுஃபையீல்ட் துறை ஆஃப் பாப்யுலேஶந் ஆரோக்கியம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

email article Hospitalized COVID-19 patients treated with high-titer convalescent plasma showed no survival benefits or clinical improvements compared to patients only receiving usual care, according to data from the U.K. s RECOVERY trial. Both groups had a mortality rate of 24% at 28 days (RR 1.00 95% CI 0.93-1.07, P=0.95), reported Peter Horby, PhD, of the University of Oxford in England, and colleagues. There was also no difference between groups in hospital stay duration or chance of disease progression, the authors wrote in This study is significant since the Recovery Collaborative Group organized the largest randomized trial in reporting COVID-19 convalescent therapy mortality results, Horby and colleagues wrote.

New yorkUnited statesPeter horbyZaina hamzaJudith abergSean liuNuffield department of population healthUniversity of oxfordIcahn school of medicineRecovery collaborative groupIcahn schoolMount sinaiNew york cityNuffield departmentPopulation healthMedpage today